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COMPARISON OF OUTCOMES AFTER TRANSPLANTATION OF UNRE-
LATED DONOR UMBILICAL CORD BLOOD VERSUS MATCHED SIBLING
BONE MARROW FOR PEDIATRIC PATIENTS WITH LEUKEMIA AND
MYELODYSPLASTIC SYNDROMES
Rodriguez-Marino, S.1, Rademaker, A.2, Kletzel, M.1, Duerst, R.1 1.
Children’s Memorial Hospital, Chicago, IL; 2. Department of Preventive
Medicine, Northwestern University, Chicago, IL
Are unrelated Umbilical Cord Blood (U-UCB) source of stem
cells equivalent to matched sibling bone marrow (MS-BM) for
treatment of pediatric patients with leukemia and myelodysplastic
syndromes (MDS)? To address this question, we retrospectively
studied the outcomes of 110 children that received a Hematopoi-
etic Stem Cell Transplant (HSCT) at Children’s Memorial Hos-
pital between 1992 and 2003 for treatment of leukemia or MDS.
Patients underwent a uniform conditioning regimen and similar
graft-vs.-host disease (GVHD) prophylaxis followed by HSCT
with either U-UCB or MS-BM. Patients receiving other regimens
or stem cell sources were excluded from this analysis. The condi-
tioning regimen was comprised of fractionated total body irradia-
tion (fTBI, 150 cGy  8  1200 cGy), etoposide (1000 mg/m2)
and cyclophosphamide (60 mg/kg/d 3d) for both stem cell
sources. GVHD prophylaxis was comprised of CsA (3 mg/kg/d),
methotrexate (15 mg/m2 day 1 and 10 mg/m2 days 3 and 6)
and (for UCB recipients) equine ATG (20 mg/kg days 1, 3, 5
and 7).
These results for HSCT in pediatric leukemia and MDS
patients suggest that relapse free survival and overall survival are
similar between these two groups and the only difference is time
to engraftment (slower in U-UCB). Thus, pediatric leukemia
patients previously considered HSCT candidates only if
MS-BM was available should be considered candidates for
HSCT if an U-UCB unit of adequate size can be identiﬁed.
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ALLOGENEIC HSCT WITH REDUCED INTENSITY CONDITIONING REGI-
MENS IN HIGH RISK PATIENTS WITH MYELOFIBROSIS
Rondelli, D.1,7, Barosi, G.2,7, Bacigalupo, A.3,7, Prchal, J.T.4,7, Popat,
U.4,7, Alessandrino, E.P.2,7, Spivak, J.L.5,7, Hoffman, R.1,7, Frucht-
man, S.6,7 1. University of Illinois at Chicago, Chicago, IL; 2. IRCCS
Policlinico San Matteo, Pavia, Pavia, Italy; 3. Ospedale San Martino,
Genova, Genova, Italy; 4. Baylor College of Medicine, Houston, TX; 5.
Johns Hopkins University, Baltimore, MD; 6. Mount Sinai School of
Medicine, New York, NY; 7. MPD Research Consortium
Idiopathic Myeloﬁbrosis (IM) is a rare chronic myeloproliferative
disorder without curative treatment. The main therapeutic option
remains transfusion support. For patients with high risk Lille
scores (Hb  10g; WBC 4,000 or 30,000) the median survival
is less than 2 years. Fully ablative allogeneic conditioning results in
a 25% peritransplant mortality, with few long term DFS in this
typically elderly group. We report on 20 patients, median age 54
yrs (range:27-68), who received a non-myeloablative allogeneic
HSC transplantation from HLA-matched related (n  18) or
unrelated (n  1), or 1Ag-mismatched related donor (n  1).
Marked splenomegaly was present in 15 pts, in the remaining 5, 3
were splenectomized. Eighteen of 20 pts had grade III/IV marrow
ﬁbrosis and 9 pts were RBC and 3 PLT transfusion-dependent.
Reduced intensity conditioning (RIC) regimens included low doses
TBI (200 cGy) and Fludara (n  5), Fludara/Melphalan (n  6),
Thiotepa/EDX (n  8) and Thiotepa/Fludara (n  1). Engraft-
ment of ANC500 and Plt20K occurred within days 12-18 and
16-77, respectively, in all pts. Chimerism analysis on d30 showed
90% donor cells in 18/20, while the remaining 2 (70% and 56%)
achieved 100% after DLI. Acute GVHD grade II-IV was observed
in 5 patients and chronic GVHD in 8 of 16 evaluable pts. Day 100
TRM was 0%. Eighteen of 20 pts (90%) are alive at 18 months
median follow-up. Two deaths were due to aGVHD and
aGVHD  aspergillosis (post DLI). Marrow ﬁbrosis was reduced
to grade 1 in the majority of the patients. CBC also improved after
transplant since median values of Hb and Plt pre- and post-Tx are:
8.1 g/dL (range: 6.2-10.7) vs 10.0 g/dL (range: 8.1-15.5), and 70 
109/L (range: 8-278) vs 110  109/L (range: 17-340), respectively.
Splenomegaly was dramatically reduced in all patients. Allogeneic
HSC transplantation with RIC regimens can be safely performed
in IM patients, with 1) low TRM 2) eradication of marrow ﬁbrosis
and massive organomegaly and 3) restoration of more normal
hematopoiesis. These provocative outcomes will prompt random-
ized trials in IM, including allogeneic transplantation for patients
with a matched donor.
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EFFECT OF COMORBIDITIES ON ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANT OUTCOMES IN AML/MDS PATIENTS IN FIRST COM-
PLETE REMISSION
Shahjahan, M., Alamo, J., de Lima, M., Khouri, I., Gajewski, J.,
Andersson, B., Champlin, R., Giralt, S.M University of Texas MD
Anderson Cancer Center, Houston, TX
Introduction: Comorbidities can have signiﬁcant impact on
both survival and treatment selection in several types of malignan-
cies. However, little attention has been paid in the literature to
assess the effect of comorbidity on transplant outcomes in hema-
tologic malignancies. We studied the impact of comorbidities on
outcomes of allogeneic hematopoietic stem cell transplant (HSCT)
in acute myeloid leukemia (AML) and myelodysplastic syndrome
(MDS) patients in 1st complete remission (CR). Methods:
Seventy-eight patients with AML or MDS who received a matched
or partially mismatched bone marrow, peripheral blood or cord
blood transplant from a related or unrelated donor between Janu-
ary 1990 and December 2001 at the University of Texas MD
Anderson Cancer Center were retrospectively reviewed. Data on
demographics, comorbid conditions, and transplant outcomes were
collected from the Blood and Marrow Transplantation database,
patient charts and institutional electronic clinical information re-
trieval system. Charlson Comorbidity Index (CCI) was used to
score comorbid conditions and CCI score was calculated for each
Table.
Stem Cell Source
Matched Sibling
BM Unrelated UCB P Value
Male/female
(number,
percent) 34 (64%), 19 (36%) 31 (54%), 26 (46%) 0.34
Age at
HSCT(years),
(median, range) 9.2 (0.5, 23.0) 7.1 (0.7-20.7) 0.47
ALL, AML, other
35 (66%), 14 (26%),
4 (8%)
23 (40%), 17 (30%),
17 (30%) 0.004
Caucasian, Hispanic,
African
American, Asian
(number,
percent)
34 (65%), 11 (21%),
3 (6%), 4 (8%)
25 (44%), 14 (25%),
13 (23%), 5 (9%) 0.04
15, 30, 45, 60 day
ANC
Engraftment
42%, 79%, 86%,
92% 4%, 48%, 91%, 95% 0.001
15, 30, 45, 60 day
Platelet
Engraftment
13%, 60%, 77%,
85% 2%, 20%, 44%, 64% 0.007
100 Days Survival
(number,
percent) 43 (81%) 44 (77%) 0.65
Chronic GVHD
(number,
percent) 4/41 (10%) 8/44 (18%) 0.35
Relapse (number,
percent) 12 (23%) 8 (14%) 0.32
1, 2, 3 Year Relapse-
free Survival 63%, 57%, 54% 61%, 53%, 53% 0.97
1, 2, 3 Year Overall
Survival 65%, 58%, 58% 57%, 50%, 50% 0.56
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patient as a weighted score of the patient’s total comorbid condi-
tions. Results: Median age was 37 years (17-67). There were 43
males  35 females. Conditioning was with Thiotepa/Busulfan
(Bu)/Cytoxan (Cy), Decitabine/Bu/Cy or Bu/Cy in 18 patients,
Fludarabine (Flu)/Melphalan in 9 patients, Flu/Ara-C/Idarubicin
in 9 patients, Flu/Bu in 7 and TBI based regimen in 35 patients.
Sixty-four patients received stem cells from a sibling donor and 14
from other related or unrelated donors. Analysis was performed
comparing patients with a CCI score of 0-2 with patients who had
a score2. These groups were also compared for patients who had
age as comorbidity and for patients who did not (age  40 yrs).
Univariate analysis showed that patients with CCI score of 0-2 had
a better overall and event free survival (OS/EFS) than patients who
had CCI score 2 (Table 1). CCI score 2 was also predictive of
non-relapse mortality (NRM). Moreover, CCI score was a stron-
ger predictor of OS, EFS and NRM in patients aged 40 years.
Conclusions: These results demonstrate the relevance of a stan-
dardized comorbidity score in predicting transplant outcomes in a
relatively homogenous population. Our analysis indicates that CCI
score can segregate patients into low or high risk for NRM and is
predictive of OS and EFS in AML/MDS patients who received an
allogeneic HSCT in 1st CR.
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STEM CELL TRANSPLANTATION FOR FANCONI ANEMIA: 20 YEARS OF
PROGRESSIVE DECREASE IN THE DOSE OF CYCLOPHOSPHAMIDE
WITHOUT IRRADIATION
Zanis Neto, J.1, Bitencourt, M.A.1, Bonﬁm, C.M.S.1, Medeiros, C.R.1,
Moreira, V.A.1, Setubal, D.C.1, Flowers, M.E.D.2, Pasquini, R.1 1.
Federal University of Parana, Curitiba, PR, Brazil; 2. Clinical Research
Division, Fred Hutchinson Cancer Research Center, Seattle, WA
Introduction: Alkylating agents and irradiation have been uti-
lized as conditioning regimen for BMT in Fanconi Anemia (FA)
for many years. FA patients (pts) are particularly hypersensitive to
these agents and its toxicity is the main cause of mortality and
morbidity after transplant. In order to decrease toxicity and main-
tain engraftment we have progressively decreased the dose of
Cyclophosphamide (CY) during the past 20 years. Material and
methods: Between 11/83 and 06/03 our BMT Unit transplanted
120 FA pts. In this study we select only pts in aplastic phase,
without myelodysplastic syndrome or leukemia. The CY doses
divided in four days were: 200 mg/kg: 10 pts; 140 mg/kg: 13 pts (8
pts received ATG 90 mg/kg or lymphoglobuline or thymoglobulin
in equivalent dose); 120 mg/kg: 8 pts; 100 mg/kg: 19 pts; 80 mg/kg:
7 pts and 60 mg/kg: 23 pts. Two pts were transplanted at the Fred
Hutchinson Cancer Research Center in Seattle (80 mg/kg: 1pt and
60 mg/kg: 1pt). All donors were full compatible HLA siblings
except in the CY60 group where there were two different full
compatible donors: a grandfather and an uncle. All pts received
cyclosporine (Csa) and methotrexate (Mtx) as GVHD immunepro-
phylaxis and prophylactic antibiotics: ﬂuconazol, sulfamethox-
azole-trimethoprim and acyclovir according to common practice.
Results: See table for pts characteristics, disease duration, previous
blood transfusions, GVHD incidence and overall survival. Chimer-
ism studies: all survivors have complete blood counts recovery to
normal values except for one pt in the CY60 group who was heavily
transfused before BMT (100 transfusions). She is now outpatient
but transfusion dependant and the VNTR shows 45% of donor
cells. Another pt in the CY60 had a late rejection (donor: grand-
father) and underwent a second transplant. He is currently alive
and well with 100% of donor cells and normal hematological
counts one year after this transplant. Conclusion: Decreasing the
dose of CY to 60mg/kg has led to a better survival, less toxicity, no
transplant related mortality and low incidence of both acute and
chronic GVHD.
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SERIOUS COMPLICATIONS FOLLOWING UNRELATED DONOR MARROW
COLLECTION: EXPERIENCES OF THE NATIONAL MARROW DONOR
PROGRAM
Confer, D.L.1, Leitman, S.F.2, Papadopoulos, E.B.3, Price, T.H.4,
Stroncek, D.F.2, Robinett, P.1, Braem, B.1, Gandham, S.1 1. National
Marrow Donor Program, Minneapolis, MN; 2. National Institutes of
Health-Transfusion Medicine, Bethesda, MD; 3. Memorial Sloan-Ket-
tering Cancer Center, New York, NY; 4. Puget Sound Blood Center,
Seattle, WA
National Marrow Donor Program®(NMDP) marrow collec-
tions between December 1987 and December 1999 (n  9282)
were evaluated to identify serious complications. Using data from
standardized individual follow-up forms, a panel of ﬁve physicians
reviewed 345 cases with potentially serious medical complications
(e.g. excessive pain, adverse acute anesthesia reactions, delayed
return to normal activities or the need for additional medical
intervention) and by consensus identiﬁed 125 (1.35% of the 9282
total) serious complications. Of the 125 serious cases, proximal
cause fell into ﬁve categories: (1) mechanical injury to tissue, bone,
or nerve (n  69, or 55% of serious subset and 0.7% of total); (2)
anesthesia (n  45, or 36% of serious subset and 0.5% of total); (3)
infection (n  1, or 0.8% of serious subset and 0.01% of total); (4)
other (n  1 [grand mal seizure], or 0.8% of serious subset and
0.01% of total); and (5) serious events thought to be unrelated to
donation (n  9 [6 cases of cancer and 3 cases of herniated spinal
disk requiring major interventions], or 7% of serious subset and
0.09% of total). The 116 donors with complications directly re-
lated to donation were further characterized according to symptom
nature and duration. Sixty-seven donors (58% and 0.7% of total)
experienced prolonged recovery periods (from months to years).
Forty-nine donors (42% and 0.5% of total) experienced severe
acute reactions, mostly related to anesthesia . Univariate and mul-
tivariate analysis indicated regional anesthesia, longer duration of
collection, female gender, and older age as signiﬁcant donor char-
acteristics for risk of serious complication. In conclusion, the in-
cidence of serious complications from marrow donation is low
(1.35%) and mechanical injury was the most frequent cause of
prolonged post collection recovery. The risks of marrow collection
Table. Effect of Comorbidity Scores on Allogeneic Transplant
Outcomes in AML/MDS Patients
Outcomes for all
patients
CCI Score 0-2
(N  28)
CCI Score >2
(N  50) P value
% OS @ 2 yrs. 83 53 0.001
% EFS @ 2 yrs. 76 38 0.0004
% NRM Day100 3 14 0.02
% NRM Day360 4 26 0.02
Outcomes for pts
<40 yrs old
CCI Score 0-2
(N  24)
CCI Score >2
(N  21) P value
% OS @ 2 yrs. 91 45 0.0009
% EFS @ 2 yrs. 83 32 0.0008
% NRM Day100 0 25 0.005
% NRM Day360 0 25 0.005
Table. Decreasing Doses of Cy for FA patients
Cy 200 Cy 140 Cy 120 Cy 100 Cy 80 Cy 60
# patients 10 13 8 19 7 23
Age-yr.-M
(range) 13 (5-32) 8 (3-30) 9 (6-19) 8 (3-22) 9 (5-16) 9 (5-29)
# previous
transf.-U-M
(range) 21 (2-151) 6 (0-200) 5 (0-100) 8 (0-100) 4 (0-50) 6 (0-101)
Disease dur.-m-
M (range) 35 (1-105) 12 (4-58) 13 (7-89) 16 (4-159) 28 (21-72) 35 (1-124)
# of MTX doses
for GVHD
prophylaxis 3 (2-4) 0 (0-4) 3 (0-4) 3 (2-4) 4 (3-4) 3 (3-4)
GVHD a III-IV
% 12.5 17 0 0 28.5 4
GVHD c
extensive % 33 27 20 12.5 33 4
Survival % 30 69 50 79 57 100
Oral Presentations
13BB&MT
